Method Article

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

DOI:

10.3791/60146

⸱

November 27th, 2019

 ,  ,  ,  ,  ,  ,  ,  ,  ,  , 
1National Institute of Immunology, 2Center for Cellular and Molecular Biology

In This Article

Summary

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The acute liver failure animal model developed in the current study presents a feasible alternative for the study of potential therapies. The current model employs the combined effect of physical and drug-induced hepatic injury and provides a suitable time window to study the potential of novel therapies.

Abstract

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Acute liver failure (ALF) is a clinical condition caused by various etiologies resulting in the loss of metabolic, biochemical, synthesizing, and detoxifying functions of the liver. In most irreversible liver damage cases, orthotropic liver transplant (OLT) remains the only available treatment. To study the therapeutic potential of a treatment for ALF, its prior testing in an animal model of ALF is essential. In the current study, an ALF model in rats was developed by combining 70% partial hepatectomy (PHx) and injections of acetaminophen (APAP) that provides a therapeutic window of 48 h. The median and left lateral lobes of the liver were removed to excise 70% of the liver mass and APAP was given 24 h postsurgically for 2 days. Survival in ALF-induced animals was found to be severely decreased. The development of ALF was confirmed by altered serum levels of the enzymes alanine amino transferase (ALT), aspartate amino transferase (AST), alkaline phosphatase (ALP); changes in prothrombin time (PT); and assessment of the international normalized ratio (INR). Study of the gene expression profile by qPCR revealed an increase in expression levels of genes involved in apoptosis, inflammation, and in the progression of liver injury. Diffused degeneration of hepatocytes and infiltration of immune cells was observed by histological evaluation. The reversibility of ALF was confirmed by the restoration of survival and serum levels of ALT, AST, and ALP after intrasplenic transplantation of syngeneic healthy rat hepatocytes. This model presents a reliable alternative to the available ALF animal models to study the pathophysiology of ALF as well as to evaluate the potential of a novel therapy for ALF. The use of two different approaches also makes it possible to study the combined effect of physical and drug-induced liver injury. The reproducibility and feasibility of current procedure is an added benefit of the model.

Introduction

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Acute liver failure (ALF) is defined by the American Association for the Study of Liver Diseases as rapid development of acute liver injury without any prior signs of damage and is characterized by severe impairment of the synthetic, metabolic, and detoxifying functions of the liver1. ALF differs from chronic liver failure where the failure occurs as a result of liver injury caused over a long period of time and from acute chronic liver failure (ACLF), where abrupt liver damage takes place as a result of chronic liver diseases2,3,4. The only available cure for ALF is orthotopic liver transplant (OLT), or death may occur. Due to the shortage of liver donors, the rate of mortality in patients suffering from ALF is very high.

To study the potential of alternative therapeutic approaches and to better understand the pathophysiology of ALF, animal models that can reflect the ALF occurring in human beings are needed. Many of the already available ALF animal models have several shortcomings. Acetaminophen (APAP) effects are difficult to reproduce but have the closest similarities in terms of temporal, clinical, biochemical, and pathological parameters. APAP- induced animal models frequently encounter problems due to the presence of methemoglobinemia caused by the oxidation of hemoglobin by APAP and its intermediates5,6,7. Another problem is the lack of reproducibility reflected by unpredictable dose responses and the time of death. The ALF animal models produced using carbon tetra chloride (CCl4) have poor reproducibility8,9,10,11. Concavalin A (Con A) and lipoplysaccharide (LPS)-induced ALF animal models do not reflect the clinical pattern of the human disease, though they have advantages in the study of cellular mechanisms involved in autoimmune liver diseases and in the study of sepsis respectively12,13,14,15. Similarly, thioacetamide (TAA) also requires biotransformation to an active metabolite thioacetamide sulfoxide and shows species variation16,17,18,19. D-galactosamine (D-Gal) produces some biochemical, metabolic, and physiological changes similar to ALF but is not able to reflect the whole ALF pathological condition20,21,22,23. There have been very few attempts to combine two or more of these methods to develop an ALF model that is able to reflect the ALF syndrome in a better manner13. Therefore, further studies are required to develop a model that can reflect the disease parameters, has better reproducibility, and provides enough time to study the effects of a therapeutic intervention.

In the current study, an alternative ALF model in rats has been created by combining the effects of partial hepatectomy (PHx) and lower doses of a hepatotoxic reagent. APAP has a well-established role in causing liver injury5,24,25. It is a widely used analgesic and is toxic to the liver at supratherapeutic doses by forming toxic metabolites. APAP is the cause of many deaths in developed countries. Physical injury caused by partial hepatectomy initiates activation of various processes involved in inflammation as well as liver regeneration. Injection of the hepatotoxic agent APAP causes a hostile environment in the liver, preventing the proliferation of hepatocytes. This reduces the stress period on the animal, which when combined with smaller doses of hepatotoxin, leads to better reproducibility of the procedure. Therefore, using this model, a combinatory effect of two types of liver injuries has been studied. To characterize the developed ALF animal model, physiological and biochemical parameters have been studied. Successful reversibility of ALF was confirmed by transplantation of syngeneic healthy rat hepatocytes.

Access restricted. Please log in or start a trial to view this content.

Protocol

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The procedure described below has been approved by the Institutional Animal Ethics Committee of National Institute of Immunology, New Delhi. The serial reference number of the approval is IAEC#355/14.

1. Preparation

  1. Prepare for the surgical procedure as described earlier by Das B et al.26.
  2. Use 6–8-week-old inbred Wistar rats with a body weight of 200–250 g.
  3. House the animals under standard animal care conditions and feed them with rat chow and libitum before and after the procedure.
  4. When performing 70% PHx, use a standard cocktail mix of ketamine hydrochloride (100 mg/kg body weight) and xylazine (10 mg/kg body weight), which is injected intraperitoneally.
    NOTE: The type of anesthetic used can have postoperative effects on the mortality and morbidity.
  5. During the cell transplant, use inhalant anesthesia Isoflurane (2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-ethane) to reduce the time of recovery of the animal after the transplantation surgery.
  6. Induce and maintain the inhalational anesthesia using a customized anesthesia system. Maintain the oxygen flow at 4 L/min. For induction use isoflurane at 4% and for maintenance use 2–3% during the surgical procedure.

2. Preoperative procedures

  1. Anesthetize the rat by injecting the ketamine-xylazine mixture described in step 3.1 intraperitoneally. Confirm the complete anesthetization by pinching the toe of the animal. Further procedures are carried out only when there is no pedal reflex.
  2. To prevent corneal desiccation, apply a carboxy methyl-cellulose based eye drop to both eyes.
  3. Restrain the anesthetized animal to a surgical board using white tape. Place the animal with the abdominal side facing up, ensuring the mouth is on the distal side from the person performing the operation.
  4. Remove hair from the upper right abdominal surgical area using an electric clipper.
  5. Disinfect the surgical site by three alternating scrubs of povidone iodine and 70% ethanol using sterilized cotton pads in circular motion.

3. Partial hepatectomy (PHx) to remove 70% of the mass of the liver

NOTE: Perform the entire surgical procedure under a sterile environment in a laminar flow hood. Use only sterile surgical instruments to minimize the risk of infection postsurgically. Removal of 70% of the liver mass, named 70% partial hepatectomy (70% PHx), was performed as described by C. Mitchell and H. Willenbring, 200827.

  1. Prior to the start of the surgery, confirm the complete anesthetization of the animal by pinching its toe. Further procedures are carried out only when there is no pedal reflex.
  2. Mark the skin to be cut just beneath the sternum, perpendicular to the xiphoid, and parallel to the ribcage.
  3. Place a sterile drape sheet having an opening of around 3 cm x 1 cm over the marked skin.
  4. Perform a transverse incision of around 2–3 cm along the marked line with a scalpel. Use surgical blade No. 22. Gently remove the attachment of the skin to the underlying muscle layer in the vicinity of the incised area using sterile moistened cotton tips.
  5. Next, make a transverse incision through the peritoneal layer just beneath the xiphoid process.
  6. With the help of two saline moistened cotton tips, expose the left lobe of the liver by applying gentle pressure on the thorax. Place one cotton tip on the diaphragmatic region of the incised portion and the other cotton tip below the incised region to lift the liver lobe up.
  7. Slip an 8–10 cm long sterile nylon thread loop (size 4–0, 0.15 mm diameter) around the exposed liver lobe. Take the loop to the base of the lobe close to the hilum with the help of microdissecting forceps or moistened cotton buds.
  8. With the help of the microsurgery needle holder and microforceps, tie the two ends of the loop, placing the knot as close to the base of the lobe as possible to constrict the blood vessel and reduce bleeding after the liver lobe is removed. Tie two additional knots on the other side.
  9. Take precaution not to tie the knot too close to the nearby blood vessels, which may otherwise cause venous obstruction (stenosis).
  10. Use microsurgery scissors to cut the tied lobe just above the knot, which leaves a discolored mass of tissue called an ischemic stump in place of the lobe.
    NOTE: The rat liver, like those of mice, is divided into four distinct lobes: the median lobe, right lateral lobe, left lateral lobe, and caudate lobe, which represent about 40%, 20%, 30%, and 7% of the total liver mass, respectively. Any combination of these lobes can be removed to excise 70% liver mass. In the current study, the median lobe and left lateral lobes were removed.
  11. Carefully locate the median lobe without damaging the remaining stump of left lateral lobe. Gently pull it out of the abdominal cavity, and at the base of the lobe tie an 8–10 cm long nylon thread (size 4–0) knot as mentioned earlier. Tie two additional knots on the other side. Carefully excise and remove the tied median lobe taking all the precautions mentioned.
  12. After removing the lobes, suture the peritoneum using an absorbable chromic 4–0 suture with continuous stitches followed by skin suturing with an interrupted suture.
  13. Apply povidone iodine on the skin surrounding the sutures to prevent infection.
  14. Remove the drape sheet and remove the animal from the surgery board.

4. Postoperative care in animals

  1. Intraperitoneally inject the animal with a dose of 12 mg cefotaxime antibiotic in 1 mL of 5% glucose solution with a 1 mL syringe to protect it from the risk of postoperative infection.
  2. Administer a subcutaneous injection of analgesic meloxicam (1 mg/kg body weight) for pain relief after surgery and follow it up by two more doses, keeping the regimen as one dose per day.
  3. House the operated animals under standard conditions of 12 h light/dark cycle and monitor at regular intervals.

5. Injection of drug in partially hepatectomized animals to induce liver failure

  1. After 24 h postsurgery, when the animals have successfully recovered from 70% PHx, measure the body weight of the animal followed by the injections.
  2. Inject 750 mg/kg body weight of APAP intraperitoneally in partially hepatectomized animals 24 h after the 70% PHx following the animals' successful recovery from the surgical procedure. Repeat the dose again after 24 h.
    NOTE: Two doses of APAP are administered intraperitoneally to the animal (i.e., 24 h and 48 h post the 70% PHx procedure, respectively).
  3. At each time point after the injection of APAP, measure the body weight of the recovering animal.
    NOTE: APAP (biocetamol) is injected in animals as a 150 mg/mL solution in 2% benzyl alcohol.

6. Transplantation of healthy hepatocytes in ALF animal models

NOTE: To study the reversibility of ALF in rats, transplant healthy syngeneic rat hepatocytes intrasplenically in the ALF-induced animals along with the 1st dose of APAP. In the current study, to provide ample time to the transplanted cells for homing and engraftment, the transplantation was done just after giving the 1st dose of APAP. Rat hepatocytes are isolated by a protocol first published by Berry and Friends et al.28 and later adapted in various other studies29,30,31 with some modifications. For intrasplenic transplantation of cells in the ALF animal model, follow the steps mentioned below.

  1. Place the rat into a poly (methyl methacrylate) chamber for induction of anesthesia with 4% isoflurane and 4 L/min oxygen flow for a rat of 250–350 g body weight. Check for the depth of anesthesia by the lack of pedal reflexes when pinching the toe of the animal.
  2. Place the anaesthetized rat on the surgical board such that its left lateral portion is facing up. Maintain anesthesia at 2–3% isoflurane inhalation through a suitable mouthpiece.
  3. Shave the skin on the left lateral region and sterilize it by povidone iodine solution.
  4. Make a transverse incision on the shaved region of skin.
  5. Make a 1–2 cm cut in the peritoneal layer to expose the spleen.
  6. Gently take out the spleen of the peritoneal cavity and lift it up with the help of two moistened cotton tips.
  7. Keep the cells (typically 107 per animal) to be transplanted suspended in 50 µL IMDM media in a 1 mL insulin syringe with a 29 G needle.
  8. Gently pierce the needle into the spleen cortex and release the cell suspension into the spleen within 2–3 min.
  9. After the cell transplantation is completed, carefully take out the needle and dab the area of the needle puncture with a moistened cotton tip to avoid leakage of the cell suspension from the site.
  10. Close the peritoneum and skin by a 4–0 absorbable suture with continuous and discontinuous suturing respectively.
  11. Apply povidone iodine solution on the skin at the place of the sutures to prevent infection on the operated site.
  12. Intraperitoneally inject 1 mL volume of 12 mg/mL of antibiotic (e.g., cefotaxime) solution and subcutaneously inject analgesic (e.g., meloxicam) 1 mg/kg body weight to the animal as a part of postoperative care. Move the animal to a warm recovering cage.
  13. Keep the operated animal in isolation under normal conditions of 12 h light/dark cycle until the surgical wounds are completely healed. This may take 3–4 days.

7. Characterization of ALF development

  1. Euthanize the animals by overdose of ketamine-xylazine solution 2 h after the 2nd dose of APAP treatment and collect blood and tissue samples.
  2. Collect serum from blood for biochemical studies32.
  3. Process liver tissue samples for histological and gene expression studies33,34,35.

Access restricted. Please log in or start a trial to view this content.

Results

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Survival percentage in animal models of ALF
The optimum dose of APAP to cause ALF in combination with 70% PHx was standardized as 750 mg/kg body weight. The treatment regimen started 24 h after 70% PHx, when the animals had completely recovered from surgery, and consisted of two APAP doses at 24 h intervals. Mortality was observed at the rate of 80% after the administration of the second dose of APAP, 48 h post-surgery. The survival percentage was analyzed and plotted via the Kaplan-Meier method (

Access restricted. Please log in or start a trial to view this content.

Discussion

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The development of an appropriate animal model for ALF is paramount for the better understanding of pathogenesis and progression of ALF. A well characterized ALF animal model also provides the opportunity for the development and trial of new therapeutic approaches against ALF. Many attempts have been made to develop a clinically relevant model of ALF6,12,21,23,46

Access restricted. Please log in or start a trial to view this content.

Disclosures

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The authors have nothing to disclose.

Acknowledgements

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

This work was supported by the core grant received from the Department of Biotechnology, Government of India to National Institute of Immunology, New Delhi.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Acetaminophen (Biocetamol)EG PharmaceuticalsNo specific Catalog Number (Local Procurement)
Alkaline Phosphatase Kit (DEA)Coral Clinical System, IndiaNo specific Catalog Number (Local Procurement)
Automated analyserTulip, Alto Santracruz, IndiaScreen Maaster 3000Biochemical analyser for liver functional test
Betadine (Povidon-Iodine Solution)Win-Medicare; IndiaNo specific Catalog Number (Local Procurement)
Biological safety cabinet (Class I)Kartos international; IndiaNo specific Catalog Number (Local Procurement)
Bright Field MicroscopeOlympus, JapanLX51
Cefotaxime (Taxim®)AlKem; Indiacefotaxime sodium injection, No specific Catalog Number (Local Procurement)
Cell StrainerSigma; USCLS431752
Collagenase Type IGibco by Life Technologies17100-017
Cotton BudsPure Swabs Pvt Ltd; IndiaNo specific Catalog Number (Local Procurement)
Drape SheetJSD Surgicals, Delhi, IndiaNo specific Catalog Number (Local Procurement)
DPX MountantSigma; US6522
Eosin Y solution, alcoholicSigma; USHT110132
ForcepsMajor Surgicals; IndiaNo specific Catalog Number (Local Procurement)
Gas Anesthesia SystemUgo Basile; Italy211000
GlucoseHimedia, IndiaGRM077
Hair removing cream (Veet®)Reckitt Benckiser, IndiaNo specific Catalog Number (Local Procurement)
Hematoxylin Solution, Mayer'sSigma; USMHS16
Heparin sodium saltHimedia; IndiaRM554
Hyaluronidase From Sheep TestesSigma; USH6254
I.V. Cannula (Plusflon)Mediplus, IndiaRef 1732411420
Insulin SyringesBD; USREF 303060
Isoflurane (Forane®)Asecia QueenboroughNo B506Inhalation Anaesthetic
Ketamine (Ketamax®)Troikaa Pharmaceuticals Ltd.Ketamine hydrochloride IP, No specific Catalog Number (Local Procurement)
Meloxicam (Melonex®)Intas Pharmaceuticals Ltd; IndiaNo specific Catalog Number (Local Procurement)
Micro needle holders straight &
curved		Mercian; EnglandBS-13-8
Micro needle holders straight &
curved		Mercian; EnglandBS-13-8
MicrotomeHisto-Line Laboratories, ItalyMRS3500
Nylon ThreadMighty; IndiaNo specific Catalog Number (Local Procurement)
ParaformaldehydeHimedia; IndiaGRM 3660
Percoll®GE Healthcare17-0891-01
Refresh Tears/Eyemist GelAllergan India Private Limited/Sun Pharma, IndiaP3060No specific Catalog Number
RPMIHimedia; IndiaNo specific Catalog Number (Local Procurement)
ScalpelMajor Surgicals; IndiaNo specific Catalog Number (Local Procurement)
ScissorsMajor Surgicals; IndiaNo specific Catalog Number (Local Procurement)
SGOT (ASAT) KITCoral Clinical System, IndiaNo specific Catalog Number (Local Procurement)
SGPT (ALAT) KITCoral Clinical System, IndiaNo specific Catalog Number (Local Procurement)
Shandon Cryotome E CryostatThermo Electron Corporation; USNo specific Catalog Number
SucroseSigma; USS0389
Surgical Blade No. 22La Medcare, IndiaNo specific Catalog Number (Local Procurement)
Surgical BoardLocally madeNo specific Catalog Number (Local Procurement)
Surgical White Tape3M India; India1530-1Micropore Surgical Tape
SuturesEthicon, Johnson & Johnson, IndiaNW 5047
Syringes (1ml, 26 G)Dispo Van; IndiaNo specific Catalog Number (Local Procurement)
Trimmer (Clipper)PhilipsNL9206AD-4 DRACHTEN QT9005
Weighing MachineBraunNo specific Catalog Number (Local Procurement)
William's E MediaHimedia; IndiaAT125
Xylazine (Xylaxin®)Indian Immunologicals LimitedSedative, Pre-Anaesthetic, Analgesic and muscle relaxant

References

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,
  1. Polson, J., Lee, W. M. AASLD position paper: the management of acute liver failure. Hepatology. 41, 1179-1197 (2005).
  2. Chung, R. T., et al. Pathogenesis of liver injury in acute liver failure. Gastroenterology. 143, 1-7 (2012).
  3. Fyfe, B., Zaldana, F., Liu, C. The Pathology of Acute Liver Failure. Clinical Liver Disease. 22, 257-268 (2018).
  4. Lefkowitch, J. H. The Pathology of Acute Liver Failure. Advances in Anatomic Pathology. 23, 144-158 (2016).
  5. Mitchell, J. R., et al. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. Journal of Pharmacology and Experimental Therapeutics. 187, 185-194 (1973).
  6. Rahman, T. M., Hodgson, H. J. Animal models of acute hepatic failure. International Journal of Clinical and Experimental Pathology. 81, 145-157 (2000).
  7. Rahman, T. M., Selden, A. C., Hodgson, H. J. A novel model of acetaminophen-induced acute hepatic failure in rabbits. Journal of Surgical Research. 106, 264-272 (2002).
  8. Dashti, H., et al. Thioacetamide- and carbon tetrachloride-induced liver cirrhosis. European Surgical Research. 21, 83-91 (1989).
  9. Demirdag, K., et al. Role of L-carnitine in the prevention of acute liver damage-induced by carbon tetrachloride in rats. Journal of Gastroenterology and Hepatology. 19, 333-338 (2004).
  10. Sheweita, S. A., Abd El-Gabar, M., Bastawy, M. Carbon tetrachloride-induced changes in the activity of phase II drug-metabolizing enzyme in the liver of male rats: role of antioxidants. Toxicology. 165, 217-224 (2001).
  11. Sinicrope, R. A., Gordon, J. A., Little, J. R., Schoolwerth, A. C. Carbon tetrachloride nephrotoxicity: a reassessment of pathophysiology based upon the urinary diagnostic indices. American Journal of Kidney Diseases. 3, 362-365 (1984).
  12. Takada, Y., Ishiguro, S., Fukunaga, K. Large-animal models of fulminant hepatic failure. Journal of Artificial Organs. 6, 9-13 (2003).
  13. Takada, Y., et al. Increased intracranial pressure in a porcine model of fulminant hepatic failure using amatoxin and endotoxin. Journal of Hepatology. 34, 825-831 (2001).
  14. Leist, M., Wendel, A. A novel mechanism of murine hepatocyte death inducible by concanavalin A. Journal of Hepatology. 25, 948-959 (1996).
  15. Mizuhara, H., et al. Strain difference in the induction of T-cell activation-associated, interferon gamma-dependent hepatic injury in mice. Hepatology. 27, 513-519 (1998).
  16. Bruck, R., et al. Hypothyroidism minimizes liver damage and improves survival in rats with thioacetamide-induced fulminant hepatic failure. Hepatology. 27, 1013-1020 (1998).
  17. Chieli, E., Malvaldi, G. Role of the microsomal FAD-containing monooxygenase in the liver toxicity of thioacetamide S-oxide. Toxicology. 31, 41-52 (1984).
  18. Fontana, L., et al. Serum amino acid changes in rats with thioacetamide-induced liver cirrhosis. Toxicology. 106, 197-206 (1996).
  19. Peeling, J., et al. Cerebral metabolic and histological effects of thioacetamide-induced liver failure. American Journal of Physiology. 265, 572-578 (1993).
  20. Blitzer, B. L., et al. A model of fulminant hepatic failure in the rabbit. Gastroenterology. 74, 664-671 (1978).
  21. Diaz-Buxo, J. A., Blumenthal, S., Hayes, D., Gores, P., Gordon, B. Galactosamine-induced fulminant hepatic necrosis in unanesthetized canines. Hepatology. 25, 950-957 (1997).
  22. Maezono, K., Mawatari, K., Kajiwara, K., Shinkai, A., Maki, T. Effect of alanine on D-galactosamine-induced acute liver failure in rats. Hepatology. 24, 1211-1216 (1996).
  23. Patzer, J. F., et al. D-galactosamine based canine acute liver failure model. Hepatobiliary & Pancreatic Diseases International. 1, 354-367 (2002).
  24. Newsome, P. N., Plevris, J. N., Nelson, L. J., Hayes, P. C. Animal models of fulminant hepatic failure: a critical evaluation. Liver Transplantation. 6, 21-31 (2000).
  25. Yoon, E., Babar, A., Choudhary, M., Kutner, M., Pyrsopoulos, N. Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update. Journal of Clinical and Translational Hepatology. 4, 131-142 (2016).
  26. Das, B., et al. Intrasplenic Transplantation of Hepatocytes After Partial Hepatectomy in NOD.SCID Mice. Journal of Visualized Experiments. , (2018).
  27. Mitchell, C., Willenbring, H. A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nature Protocols. 3, 1167-1170 (2008).
  28. Berry, M. N., Friend, D. S. High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. Journal of Cell Biology. 43, 506-520 (1969).
  29. Fry, J. R., Jones, C. A., Wiebkin, P., Bellemann, P., Bridges, J. W. The enzymic isolation of adult rat hepatocytes in a functional and viable state. Analytical Biochemistry. 71, 341-350 (1976).
  30. Green, C. J., et al. The isolation of primary hepatocytes from human tissue: optimising the use of small non-encapsulated liver resection surplus. Cell Tissue Bank. 18, 597-604 (2017).
  31. Ismail, T., et al. Growth of normal human hepatocytes in primary culture: effect of hormones and growth factors on DNA synthesis. Hepatology. 14, 1076-1082 (1991).
  32. Greenfield, E. A. Sampling and Preparation of Mouse and Rat Serum. Cold Spring Harbor Protocols. 11, (2017).
  33. Walsh, K. M., Timms, P., Campbell, S., MacSween, R. N., Morris, A. J. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Digestive Diseases and Sciences. 44, 624-630 (1999).
  34. Thiele, N. D., et al. TIMP-1 is upregulated, but not essential in hepatic fibrogenesis and carcinogenesis in mice. Scientific Reports. 7, 714(2017).
  35. Li, C. P., Li, J. H., He, S. Y., Li, P., Zhong, X. L. Roles of Fas/Fasl, Bcl-2/Bax, and Caspase-8 in rat nonalcoholic fatty liver disease pathogenesis. Genetics and Molecular Research. 13, 3991-3999 (2014).
  36. Kim, W. R., Flamm, S. L., Di Bisceglie, A. M., Bodenheimer, H. C. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 47, 1363-1370 (2008).
  37. Henry, L. Serum transaminase levels in liver disease. Journal of Clinical Pathology. 12, 131-137 (1959).
  38. Giannini, E. G., Testa, R., Savarino, V. Liver enzyme alteration: a guide for clinicians. Canadian Medical Association Journal. 172, 367-379 (2005).
  39. Hammam, O., et al. The role of fas/fas ligand system in the pathogenesis of liver cirrhosis and hepatocellular carcinoma. Hepatitis Monthly. 12, 6132(2012).
  40. Prystupa, A., et al. Activity of MMP-2, MMP-8 and MMP-9 in serum as a marker of progression of alcoholic liver disease in people from Lublin Region, eastern Poland. The Annals of Agricultural and Environmental Medicine. 22, 325-328 (2015).
  41. Sekiyama, K. D., Yoshiba, M., Thomson, A. W. Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clinical and Experimental Immunology. 98, 71-77 (1994).
  42. Schwabe, R. F., Brenner, D. A. Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. American Journal of Physiology-Gastrointestinal and Liver Physiology. 290, 583-589 (2006).
  43. Ataseven, H., et al. The levels of ghrelin, leptin, TNF-alpha, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection. Mediators of Inflammation. 2006, 78380(2006).
  44. Ambrosino, G., et al. Cytokines and liver failure: modification of TNF- and IL-6 in patients with acute on chronic liver decompensation treated with Molecular Adsorbent Recycling System (MARS). Acta Bio Medica Atenei Parmensis. 74, Suppl 2 7-9 (2003).
  45. Robert, A., Chazouilleres, O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio. Hepatology. 24, 1392-1394 (1996).
  46. Francavilla, A., et al. A dog model for acetaminophen-induced fulminant hepatic failure. Gastroenterology. 96, 470-478 (1989).
  47. Terblanche, J., Hickman, R. Animal models of fulminant hepatic failure. Digestive Diseases and Sciences. 36, 770-774 (1991).
  48. Tunon, M. J., et al. Rabbit hemorrhagic viral disease: characterization of a new animal model of fulminant liver failure. Journal of Laboratory and Clinical Medicine. 141, 272-278 (2003).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

Acute Liver FailurePartial HepatectomyAcetaminophen HepatotoxicityRat ModelSurgical ProcedureBiochemical AnalysisHistological EvaluationGene ExpressionHepatocyte TransplantationSurvival Assessment

Related Articles